EUVIMEDEUVIMED entdecken
Crossref

Developing Chlorin/Arylaminoquinazoline Conjugates with Nanomolar Activity for Targeted Photodynamic Therapy: Design, Synthesis, SAR, and Biological Evaluation

Lubov V Krylova, Vasilii F Otvagin iD, Galina P Gribova iD, Natalia S Kuzmina, Ekaterina A Fedotova, Ivan V Zelepukin iD, Alexander V Nyuchev iD, Andrey V Kustov, Philipp K Morshnev iD, Dmitry B Berezin, Mikhail O Koifman, Sergey Z Vatsadze iD und 2 weitere

Journal of Medicinal Chemistry · 23.01.2025 · 68 (2) · 1901-1923

DOI: 10.1021/acs.jmedchem.4c02643 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 02.01.2025. Verfasst von Lubov V Krylova und 13 weiteren Autor:innen. Beteiligte Einrichtung: Lobachevsky State University of Nizhny Novgorod, Gagarina av. 23, Nizhny Novgorod 603950, Russian Federation. Hauptthemen laut MEDLINE: Drug Design, Mice, Nude, Photochemotherapy, Photosensitizing Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 72 Literaturangaben. Gefördert von: Russian Science Foundation, Ministry of Science and Higher Education of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this report, we developed novel chlorin/arylaminoquinazoline conjugates for targeted photodynamic therapy of cancer. The synthesized photosensitizers consisted of chlorin-e6 metallocomplexes (Zn, In, or Pd) conjugated with arylaminoquinazoline ligands with high affinity for epidermal growth factor receptors (EGFR). Additionally, the selectivity and antitumor properties of the conjugates were investigated in the EGFR-expressing A431 human tumor cell line in vitro. Among the tested molecules, the In-containing conjugate effectively inhibited tumor cell proliferation at nanomolar concentrations, a rare property for conventional photosensitizers. In in vivo experiments, the conjugates rapidly accumulated at the tumor site in nude mice bearing A431 xenograft tumors. Subsequent distribution analysis among different tissues was carried out using fluorescence imaging and elemental analysis. Finally, we demonstrated that the most promising In-containing conjugate was capable of inhibiting xenograft tumor growth in mice through combinational therapy. This therapeutic approach, combined with the conjugate's confirmed safety profile, highlights its potential for effective and safe cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DesignMice, NudePhotochemotherapyPhotosensitizing AgentsPorphyrinsQuinazolinesAnimalsHumansMiceAntineoplastic AgentsCell Line, TumorCell ProliferationErbB ReceptorsMice, Inbred BALB CStructure-Activity RelationshipXenograft Model Antitumor AssaysCoordination Complexes

Substanzen

Antineoplastic AgentschlorinErbB ReceptorsPhotosensitizing AgentsPorphyrinsQuinazolinesCoordination Complexes

Autor:innen und Institutionen

  • Lobachevsky State University of Nizhny Novgorod, Gagarina av. 23, Nizhny Novgorod 603950, Russian Federation.
  • Uppsala University, Dag Hammarskjölds väg, 20751 85 Uppsala, Sweden.
  • G.A. Krestov Institute of Solution Chemistry, Russian Academy of Sciences, Ivanovo 153045, Russian Federation.
  • Institute of Macroheterocyclic Compounds, Ivanovo State University of Chemistry and Technology, Ivanovo 153012, Russian Federation.
  • N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 47 Leninsky Prosp., Moscow 119991, Russian Federation.

ORCID-Profile: Vasilii F Otvagin, Galina P Gribova, Ivan V Zelepukin, Alexander V Nyuchev, Philipp K Morshnev, Sergey Z Vatsadze, Irina V Balalaeva, Alexey Yu Fedorov

Förderung

  • Russian Science Foundation
  • Ministry of Science and Higher Education of the Russian Federation

Zitieren

APA

Krylova, L. V., Otvagin, V. F., Gribova, G. P., Kuzmina, N. S., Fedotova, E. A., Zelepukin, I. V., Nyuchev, A. V., Kustov, A. V., Morshnev, P. K., Berezin, D. B., Koifman, M. O., Vatsadze, S. Z., Balalaeva, I. V., & Fedorov, A. Y. (2025). Developing Chlorin/Arylaminoquinazoline Conjugates with Nanomolar Activity for Targeted Photodynamic Therapy: Design, Synthesis, SAR, and Biological Evaluation. Journal of Medicinal Chemistry, 68(2), 1901-1923. https://doi.org/10.1021/acs.jmedchem.4c02643

Vancouver

Krylova LV, Otvagin VF, Gribova GP, Kuzmina NS, Fedotova EA, Zelepukin IV, et al. Developing Chlorin/Arylaminoquinazoline Conjugates with Nanomolar Activity for Targeted Photodynamic Therapy: Design, Synthesis, SAR, and Biological Evaluation. Journal of Medicinal Chemistry. 2025;68(2):1901-1923. doi:10.1021/acs.jmedchem.4c02643

BibTeX
@article{Krylova2025,
  author = {Krylova, Lubov V and Otvagin, Vasilii F and Gribova, Galina P and Kuzmina, Natalia S and Fedotova, Ekaterina A and Zelepukin, Ivan V and Nyuchev, Alexander V and Kustov, Andrey V and Morshnev, Philipp K and Berezin, Dmitry B and Koifman, Mikhail O and Vatsadze, Sergey Z and Balalaeva, Irina V and Fedorov, Alexey Yu},
  title = {Developing Chlorin/Arylaminoquinazoline Conjugates with Nanomolar Activity for Targeted Photodynamic Therapy: Design, Synthesis, SAR, and Biological Evaluation},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {2},
  pages = {1901--1923},
  doi = {10.1021/acs.jmedchem.4c02643}
}
Kostenlos starten →